Tango Therapeutics
TNGX
39 hedge funds and large institutions have $150M invested in Tango Therapeutics in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
12% more capital invested
Capital invested by funds: $135M → $150M (+$15.7M)
3% more funds holding
Funds holding: 38 → 39 (+1)
0.55% more ownership
Funds ownership: 63.33% → 63.87% (+0.55%)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.57M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$273K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$166K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$105K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$90.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.02M |
| 2 |
CIM
Cowen Investment Management
New York
|
-$790K |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$461K |
| 4 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
-$384K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$259K |
TNGX Hedge Fund Activity: Q4 2020 in Review
39 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q4 2020, worth a combined $150M — up 12% from $135M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TNGX positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 9 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $1.57M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $1.02M sold.
- 39 institutional investors held Tango Therapeutics (TNGX) as of Q4 2020, up from 38 in Q3 2020.
- Funds reported $150M of Tango Therapeutics stock for Q4 2020, up 12% quarter-over-quarter.
- 7 funds opened new Tango Therapeutics positions in Q4 2020 and 6 closed out, a net change of +1 holder.
- The largest Tango Therapeutics buyer in Q4 2020 was Ikarian Capital, an estimated $1.57M added.
- The largest Tango Therapeutics seller in Q4 2020 was JP Morgan Chase, an estimated $1.02M sold.
Based on aggregated 13F filings for Q4 2020.